Phase 2 study of pembrolizumab in patients with advanced rare cancers
Aung Naing(The University of Texas MD Anderson Cancer Center), Mouhammed Amir Habra(The University of Texas MD Anderson Cancer Center), Daniel D. Karp(The University of Texas MD Anderson Cancer Center), Shi‐Ming Tu(The University of Texas MD Anderson Cancer Center), David S. Hong(The University of Texas MD Anderson Cancer Center), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Camilo Jiménez(The University of Texas MD Anderson Cancer Center), Matthew D. Campbell(The University of Texas MD Anderson Cancer Center), Vivek Subbiah(Sarah Cannon), Apostolia M. Tsimberidou(The University of Texas MD Anderson Cancer Center), Sara Ahmed(The University of Texas MD Anderson Cancer Center), Siqing Fu(The University of Texas MD Anderson Cancer Center), Linghua Wang(The University of Texas MD Anderson Cancer Center), Chantale Bernatchez(BMC Software (United States)), Vinod Ravi(Unknown), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Anas Alshawa(The University of Texas MD Anderson Cancer Center), Joud Hajjar(Baylor College of Medicine), Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Abdulrahman Abonofal(The University of Texas MD Anderson Cancer Center), Filip Jankú(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Bettzy Stephen(The University of Texas MD Anderson Cancer Center), Michael Frumovitz(The University of Texas MD Anderson Cancer Center), Shubham Pant(The University of Texas MD Anderson Cancer Center), Rivka R. Colen(The University of Texas MD Anderson Cancer Center), Mingxuan Xu(The University of Texas MD Anderson Cancer Center), Sarjeel H Sabir(The University of Texas MD Anderson Cancer Center), Jing Gong(174th hospital of the People's Liberation Army), Richard Simon(University of Chicago), Coya Tapia(The University of Texas MD Anderson Cancer Center), Saria Khan(The University of Texas MD Anderson Cancer Center), Jeane M. Painter(The University of Texas MD Anderson Cancer Center), Lacey McQuinn(The University of Texas MD Anderson Cancer Center), Ecaterina E. Dumbrava(The University of Texas MD Anderson Cancer Center), Kenneth R. Hess(The University of Texas MD Anderson Cancer Center), Gauri R. Varadhachary(The University of Texas MD Anderson Cancer Center), Renata Ferrarotto(The University of Texas MD Anderson Cancer Center)
Cited by 130
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k